search
Back to results

Effect of Moringa Oleifera Infusion on Health (MOI)

Primary Purpose

Metabolic Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Mauritius
Study Type
Interventional
Intervention
Moringa oleifera tea
Sponsored by
University of Mauritius
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Metabolic Syndrome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy subjects with normal fasting plasma glucose levels
  • Individuals with pre-diabetes condition newly diagnosed
  • Individuals with dyslipidemia
  • Type 2 Diabetes patients taking oral allopathic hypoglycemic agents

Exclusion Criteria:

  • Pregnant women
  • Smokers
  • People with alcohol intake >2 standard drinks per day (in line with Bahorun et al. 2012)
  • Patients with any complications of diabetes mellitus
  • Patients on insulin therapy (in line with Leone et al. 2018)
  • Patients with gastro-intestinal, hepatic, cardiovascular, renal or endocrine disorder (other than diabetes mellitus) which can interfere with the absorption, metabolism and excretion of Moringa leaves (in line with Bahorun et al. 2012)
  • Patients on medication for diseases other than diabetes
  • Persons taking botanical extracts
  • People currently on a diet (in line with Ahmad et al. 2018)
  • People having food allergies.

Sites / Locations

  • University of Mauritius

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Drinking Moringa oleifera tea

Drinking plain water

Arm Description

The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.

The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.

Outcomes

Primary Outcome Measures

Change in blood glucose level
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)
Change in Low-density Lipoprotein (LDL) Cholesterol level
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)
Change in Triglyceride level
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)

Secondary Outcome Measures

Change in levels of blood anti-oxidants
Levels of blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity) will be monitored every fortnight during the 8-week clinical trial. C-Reactive Protein will also be measured.

Full Information

First Posted
February 18, 2020
Last Updated
March 17, 2020
Sponsor
University of Mauritius
search

1. Study Identification

Unique Protocol Identification Number
NCT04314258
Brief Title
Effect of Moringa Oleifera Infusion on Health
Acronym
MOI
Official Title
Randomized Clinical Study Investigating the Effect of Moringa Oleifera Infusion on Bioclinical Parameters of Health
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
February 10, 2020 (Actual)
Primary Completion Date
April 30, 2020 (Anticipated)
Study Completion Date
August 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Mauritius

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study aims at investigating the effects of the consumption of Moringa oleifera Lam leaves on biomedical markers of health among healthy individuals who are hyperglycaemic with a fasting blood glucose equal or greater than 5.5mmol/L. The main objectives are as follows: To determine the effect of consuming 4 grams of Moringa oleifera Lam leaves infused in 200 ml of hot water twice daily on blood glucose level [BSc (Hons) Medical Science Student]. To assess the effect of consuming 4 grams of Moringa oleifera Lam leaves infused in 200 ml of hot water twice daily on plasma lipids level [Master of Public Health Students]. To compare the effect of the Moringa tea consumption on lipid profiles of both healthy and hyperglycemic participants [Master of Public Health Students]. To evaluate the effects of Moringa oleifera Lam leaves on blood anti-oxidant status [BSc (Hons) Nutritional Sciences Student]. The research work will consist of (1) Experimental intervention: The experimental group will drink Moringa tea; (2) Survey questionnaire, (3) Anthropometric measurements, (4) Blood pressure determination and (5) Blood collections at 15-day intervals during 9 weeks. The blood tests to be performed are as follows: Glucose, HbA1C, Uric acid, C-Protein reactive, Lipid Profile (Total Cholesterol, HDL Cholesterol, Triglycerides), and blood antioxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity).
Detailed Description
Study population 120 participants to include 60 healthy individuals and 60 individuals who are hyperglycaemic with a fasting blood glucose equal or greater than 5.5mmol/L will be recruited by means of flyers, posters and mass email by the help of Staff Club of the UoM. Experimental design This research work will to be undertaken under the responsibility and coordination of the Applicant who is the Principal Investigator working with two Academic Supervisors for the supervision of the four student projects. This randomized clinical study will consist of two parallel groups with a crossover design. There will be two arms as follows for each group: Intervention group [drinking Moringa tea] and Control group [drinking plain water]. Computer-generated random numbers will be used for simple randomization of subjects to either the experimental or control (equal amount of water) groups. Half of the participants will be assigned to the experimental group and the other control (water) for the first 4 weeks during Phase 1. The experimental group will be provided with Moringa tea bags and instructed to consume twice daily 2 tea bags (4 tea bags equivalent to 8 grams) of Moringa tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study. With the cross over design, there will be two phases for both healthy and hyperglycaemic groups with an interchange of the groups during Phase 1 and 2 as follows: Four-week Phase 1 - Group A drinking Moringa tea v/s Group B drinking plain water One-week washout Four-week Phase 2 - Group A drinking plain water v/s Group B drinking Moringa tea The duration of the clinical study will normally be nine weeks with possible extension of four weeks. Outcome Measurements Baseline data collection Measurements of body weight and blood pressure will be performed. Anthropometric measurements will be taken for each subject: Weight will be measured using an electronic weighing machine, height will be measured using a stadiometer, waist circumference will be measured using a non-stretchable measuring tape. Blood pressure will be measured using a sphygmomanometer. Blood samples will be drawn by Specialized Nursing Officers from right or left ante-cubital vein of participant after a 12-h overnight fast. Blood tests which will be performed are as follows: Glucose, Lipid profile [Triglycerides, Total Cholesterol and HDL Cholesterol levels (LDL Cholesterol being calculated)], Uric Acid, HbA1C, C-Reactive Protein (hs-CRP) and Blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity). Fortnight monitoring sessions All participants of the two groups will be monitored on a fortnight basis for body weight, height, waist circumference, blood pressure and specified blood tests. Food intake and physical exercise questionnaires will be collected from participants to determine confounding factors. [The individual quantity of physical activity, in metabolic equivalent-minutes per week (MET-min/week), will be determined by using validated physical activity questionnaire]. Outcome Measurements Baseline data collection Measurements of body weight and blood pressure will be performed. Anthropometric measurements will be taken for each subject: Weight will be measured using an electronic weighing machine, height will be measured using a stadiometer, waist circumference will be measured using a non-stretchable measuring tape. Blood pressure will be measured using a sphygmomanometer. Blood samples will be drawn by Specialized Nursing Officers from right or left ante-cubital vein of participant after a 12-h overnight fast. Blood tests which will be performed are as follows: Glucose, Lipid profile [Triglycerides, Total Cholesterol and HDL Cholesterol levels (LDL Cholesterol being calculated)], Uric Acid, HbA1C, C-Reactive Protein (hs-CRP) and Blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity). Fortnight monitoring sessions All participants of the two groups will be monitored on a fortnight basis for body weight, height, waist circumference, blood pressure and specified blood tests. Food intake and physical exercise questionnaires will be collected from participants to determine confounding factors. [The individual quantity of physical activity, in metabolic equivalent-minutes per week (MET-min/week), will be determined by using validated physical activity questionnaire].

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
This randomized clinical study will consist of two parallel groups with a crossover design. There will be two arms as follows: Intervention group [Drinking Moringa tea] Control group [Drinking plain water]. Computer-generated random numbers will be used for simple randomization of subjects to either the experimental or control group. With the cross over design, there will be two phases with an interchange of the groups during Phase 1 and 2 as follows: Four-week Phase 1 - Group A drinking Moringa tea v/s Group B drinking plain water One-week washout Four-week Phase 2 - Group A drinking plain water v/s Group B drinking Moringa tea
Masking
Outcomes Assessor
Masking Description
A coding system will be used whereby each subject will be attributed a code upon signing the consent form. Only the Principal Investigator assisted by a second investigator will have access to the name-code list.
Allocation
Randomized
Enrollment
103 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Drinking Moringa oleifera tea
Arm Type
Experimental
Arm Description
The experimental group will drink twice daily 2 tea bags of Moringa oleifera tea (Kanhye brand) infused in 200 ml of hot water (during 5 minutes) for a period of 4 weeks. The locally available Moringa tea with the international certification by ECOCERT France will be used in this study.
Arm Title
Drinking plain water
Arm Type
No Intervention
Arm Description
The control group will receive instructions to consume 200 ml of plain water twice daily for a period of 4 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Moringa oleifera tea
Intervention Description
4 grams of Moringa oleifera tea twice daily
Primary Outcome Measure Information:
Title
Change in blood glucose level
Description
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)
Time Frame
Eight weeks
Title
Change in Low-density Lipoprotein (LDL) Cholesterol level
Description
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)
Time Frame
Eight weeks
Title
Change in Triglyceride level
Description
Change will be determined as the value at Day 29 with respect to Day 1 for Phase 1 (Four weeks) and for Phase 2 (four weeks)
Time Frame
Eight weeks
Secondary Outcome Measure Information:
Title
Change in levels of blood anti-oxidants
Description
Levels of blood anti-oxidants (superoxide dismutase, glutathione peroxidase, total blood anti-oxidant capacity) will be monitored every fortnight during the 8-week clinical trial. C-Reactive Protein will also be measured.
Time Frame
Eight weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy subjects with normal fasting plasma glucose levels Individuals with pre-diabetes condition newly diagnosed Individuals with dyslipidemia Type 2 Diabetes patients taking oral allopathic hypoglycemic agents Exclusion Criteria: Pregnant women Smokers People with alcohol intake >2 standard drinks per day (in line with Bahorun et al. 2012) Patients with any complications of diabetes mellitus Patients on insulin therapy (in line with Leone et al. 2018) Patients with gastro-intestinal, hepatic, cardiovascular, renal or endocrine disorder (other than diabetes mellitus) which can interfere with the absorption, metabolism and excretion of Moringa leaves (in line with Bahorun et al. 2012) Patients on medication for diseases other than diabetes Persons taking botanical extracts People currently on a diet (in line with Ahmad et al. 2018) People having food allergies.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie CHAN SUN, PhD
Organizational Affiliation
University of Mauritius
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Vidushi NEERGHEEN, PhD
Organizational Affiliation
University of Mauritius
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Abha JODHEEA-JUTTON, MD
Organizational Affiliation
University of Mauritius
Official's Role
Study Chair
Facility Information:
Facility Name
University of Mauritius
City
Moka
State/Province
Please Select
ZIP/Postal Code
80811
Country
Mauritius

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.
IPD Sharing Time Frame
2022-2025
IPD Sharing Access Criteria
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.
Citations:
PubMed Identifier
22198621
Citation
Bahorun T, Luximon-Ramma A, Neergheen-Bhujun VS, Gunness TK, Googoolye K, Auger C, Crozier A, Aruoma OI. The effect of black tea on risk factors of cardiovascular disease in a normal population. Prev Med. 2012 May;54 Suppl:S98-102. doi: 10.1016/j.ypmed.2011.12.009. Epub 2011 Dec 16.
Results Reference
background
PubMed Identifier
30322091
Citation
Leone A, Bertoli S, Di Lello S, Bassoli A, Ravasenghi S, Borgonovo G, Forlani F, Battezzati A. Effect of Moringa oleifera Leaf Powder on Postprandial Blood Glucose Response: In Vivo Study on Saharawi People Living in Refugee Camps. Nutrients. 2018 Oct 12;10(10):1494. doi: 10.3390/nu10101494.
Results Reference
background
PubMed Identifier
29272206
Citation
Ahmad J, Khan I, Johnson SK, Alam I, Din ZU. Effect of Incorporating Stevia and Moringa in Cookies on Postprandial Glycemia, Appetite, Palatability, and Gastrointestinal Well-Being. J Am Coll Nutr. 2018 Feb;37(2):133-139. doi: 10.1080/07315724.2017.1372821. Epub 2017 Dec 22.
Results Reference
background
Citation
Kumari, D. J. (2010) 'Hypoglycaemic Effect of Moringa Oleifera and Azadirachta Indica in Type 2 Diabetes Mellitus', The Bioscan, 5(2), p. 4.
Results Reference
background

Learn more about this trial

Effect of Moringa Oleifera Infusion on Health

We'll reach out to this number within 24 hrs